July 2026
Added to Dediabetes Jul 12, 2026RCTs
This study examined the impact of an Integrative Complementary Medicine (ICM) program on the quality of life in cancer patients with diabetes, revealing significant differences in drowsiness and emotional functioning.
Interventions
Integrative Complementary Medicine (ICM) Program
Outcomes
Drowsiness measured using the Edmonton Symptom Assessment Scale (ESAS)Emotional Functioning as Measured by EORTC QLQ-C30Fatigue on ESAS+1 more
Added to Dediabetes Jul 12, 2026RCTs
The Reduction of Cardiovascular Events with Icosapent Ethyl-Intervention Trial demonstrated that Icosapent ethyl significantly reduced cardiovascular events compared to placebo.
Interventions
Icosapent ethyl
Outcomes
Absolute cardiovascular risk reductionComposite cardiovascular events (CV death, MI, stroke, HF hospitalization)Major adverse cardiovascular events, 5-point composite
Added to Dediabetes Jul 12, 2026RCTs
Switching from premixed insulin to the insulin glargine/lixisenatide fixed-ratio combination (iGlarLixi) improved glycemic control in participants with type 2 diabetes.
Interventions
Insulin glargine/lixisenatide fixed-ratio combination (iGlarLixi)
Outcomes
Body weightDiabetes-related misconceptionsFasting blood sugar (FBS)+3 more
Added to Dediabetes Jul 12, 2026Cohort
This study analyzed the long-term cost-effectiveness of IDegLira for treating type 2 diabetes in China, showing significant improvements in glycemic control and health outcomes.
Outcomes
BMIDiabetic neuropathy incidenceDiabetic retinopathy incidence+11 more
Added to Dediabetes Jul 12, 2026RCTs
This study analyzed the relationship between insulin-like growth factor-1 (IGF-1) levels and cardiovascular outcomes in hyperglycemic acute coronary syndrome patients, finding no independent association with major adverse cardiovascular events.
Interventions
Intensive glycemic control
Outcomes
Composite cardiovascular events (CV death, MI, stroke, HF hospitalization)Post-ACS myocardial infarct size and left ventricular functionType 2 diabetes incidence
Added to Dediabetes Jul 12, 2026RCTs
This study evaluated the effectiveness of insulin glargine-lixisenatide fixed-ratio combination (iGlarLixi) in individuals with type 2 diabetes. It found significant improvements in body weight, BMI, and insulin dosage compared to multiple daily injections (MDI).
Interventions
Insulin glargine/lixisenatide fixed-ratio combination (iGlarLixi)
Outcomes
Body Mass Index (BMI) changeGlycemia risk indexHbA1c+3 more
Added to Dediabetes Jul 12, 2026RCTs
The study evaluated the impact of iGlarLixi on treatment satisfaction in adults with Type 2 Diabetes, showing improvements in satisfaction scores and time in range.
Interventions
Insulin glargine/lixisenatide fixed-ratio combination (iGlarLixi)
Outcomes
Time in rangeTreatment satisfaction
Added to Dediabetes Jul 12, 2026RCTs
This study evaluated a concentrated transdiagnostic treatment for patients with Type 2 diabetes and sleep disorders, showing significant improvements in sleep-related outcomes over 12 months.
Interventions
Concentrated transdiagnostic, micro choice-based and interdisciplinary group treatment
Outcomes
Reduction in Daytime Sleepiness Measured by Epworth Sleepiness ScaleReduction in Insomnia Symptoms Measured by Bergen Insomnia ScaleReduction in Insomnia Symptoms Measured by Insomnia Severity Index (ISI)+1 more
Added to Dediabetes Jul 12, 2026RCTs
This study evaluated an educational intervention aimed at improving sleep hygiene in patients with type 2 diabetes, showing significant improvements in sleep quality and metabolic markers at 3 months.
Interventions
Educational intervention to improve sleep hygiene
Outcomes
Fasting Plasma Glucose (FPG)HbA1cSleep efficiency+2 more
Added to Dediabetes Jul 12, 2026RCTs
This study analyzed insulin requirements in children and adolescents with Type 1 Diabetes using a closed-loop insulin delivery system. It found significant increases in total daily insulin doses and the proportion of basal insulin over 48 months.
Interventions
Hybrid closed-loop system
Outcomes
Day-to-day variability of insulin requirements measured as coefficient of variationProportion of total daily insulin delivered as basal insulinTotal daily insulin dose
